A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair by Parrotta, Rossella et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2017
A novel BRCA1-associated protein-1 isoform affects response of
mesothelioma cells to drugs impairing BRCA1-mediated DNA repair
Parrotta, Rossella; Okonska, Agata; Ronner, Manuel; Weder, Walter; Stahel, Rolf; Penengo, Lorenza;
Felley-Bosco, Emanuela
DOI: https://doi.org/10.1016/j.jtho.2017.03.023
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-136745
 
 
Originally published at:
Parrotta, Rossella; Okonska, Agata; Ronner, Manuel; Weder, Walter; Stahel, Rolf; Penengo, Lorenza;
Felley-Bosco, Emanuela (2017). A novel BRCA1-associated protein-1 isoform affects response of mesothe-
lioma cells to drugs impairing BRCA1-mediated DNA repair. Journal of Thoracic Oncology, 12(8):1309-
1319.
DOI: https://doi.org/10.1016/j.jtho.2017.03.023
BRIEF REPORT
A Novel BRCA1-Associated Protein-1 Isoform Affects
Response of Mesothelioma Cells to Drugs Impairing
BRCA1-Mediated DNA Repair
Rossella Parrotta, PhD,a Agata Okonska, MSc,a Manuel Ronner,a Walter Weder, MD,b
Rolf Stahel, MD,c Lorenza Penengo, PhD,d Emanuela Felley-Bosco, PhDa,*
aLaboratory of Molecular Oncology, Division of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland
bDivision of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland
cCancer Center Zürich, University Hospital Zürich, Zürich, Switzerland
dInstitute of Molecular Cancer Research, University of Zürich, Zürich, Switzerland
Received 12 September 2016; revised 8 March 2017; accepted 21 March 2017
Available online - 4 April 2017
ABSTRACT
Introduction: BRCA1 associated protein1 (BAP1) is a tu-
mor suppressor involved in multiple cellular processes such
as transcriptional regulation, chromatin modiﬁcation by
deubiquitinating histone 2A, and DNA repair. BAP1 muta-
tions are frequent in malignant pleural mesothelioma
(MPM). Our aim was to functionally characterize a newly
identiﬁed isoform of BAP1 and investigate the effects of its
expression on drug sensitivity in MPM.
Methods: Expression of BAP1 isoforms was detected by
quantitative polymerase chain reaction in MPM and normal
mesothelium cell lines and tumor and nontumor samples.
Histone H2A ubiquitination levels were analyzed by
Western blot after acidic extraction of core histones.
Subcellular localization of BAP1 isoforms was examined by
immunoﬂuorescence. MPM cell survival in response to
poly(adenosine diphosphate–ribose) polymerase (PARP)
and dual phosphoinositide 3–kinase (PI3K)–mammalian
target of rapamycin (mTOR) inhibitors was analyzed by
in vitro assays.
Results: We have identiﬁed a novel alternative splice iso-
form of BAP1 (BAP1D) that misses part of the catalytic
domain. Cells transfected with BAP1D showed reduced
deubiquitinating activity compared with full-length BAP1.
The expression of BAP1D transcript is more abundant in
nontumor than in tumor samples. MPM cell lines expressing
more than 20% of BAP1D are more sensitive to olaparib
(a PARP1 inhibitor) cytotoxicity, and this sensitivity is
enhanced when olaparib treatment is combined with
GDC0980 (a dual PI3K-mTOR inhibitor), which induces
downregulation of BRCA1.
Conclusions: These observations suggest that BAP1D does
regulate DNA damage response and inﬂuences drug
sensitivity. It might therefore be relevant to investigate
whether patients with high expression of BAP1D may be
responsive to PARP/PI3K-mTOR inhibitors.
 2017 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: BRCA1 associated protein 1; Mesothelioma;
PARP inhibition; BRCA1
Introduction
BRCA1-associated protein-1 (BAP1) loss-of-function
mutations have been described as one of the main
drivers in the complex pathogenesis of malignant pleural
mesothelioma (MPM).1–4 Germline loss of BAP1 leads to
a predisposition for different types of cancer, including
mesothelioma.5 BAP1 was initially identiﬁed in lung
cancer cell lines as a protein that binds to BRCA1,
DNA repair associated (BRCA1),6 which is a well-known
*Corresponding author.
Dr. Parrotta and Ms. Okonska equally contributed to this work.
Disclosure: The authors declare no conﬂict of interest.
Address for correspondence: Emanuela Felley-Bosco, PhD, Laboratory
of Molecular Oncology, Thoracic Surgery, University Hospital Zürich,
8091 Zürich, Switzerland. E-mail: emanuela.felley-bosco@usz.ch
ª 2017 International Association for the Study of Lung Cancer.
Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
ISSN: 1556-0864
http://dx.doi.org/10.1016/j.jtho.2017.03.023
Journal of Thoracic Oncology Vol. - No. -: ---
tumor suppressor that is involved in maintenance of
genomic stability and participates in DNA repair of
double-strand breaks (DSBs).7,8 BAP1 is a 90-kDa
nuclear-localized deubiquitinating enzyme with ubiq-
uitin carboxyl hydrolase (UCH) activity, and it is the only
member of the UCH family with two nuclear localization
signal motifs.9 BAP1-mediated tumor suppression
requires both deubiquitinating activity and nuclear
localization of BAP1.9 BAP1 in a complex with the
polycomb group protein additional sex combs like 1,
transcriptional regulator is essential for histone 2A
(H2A) deubiquitination,10 resulting in chromatin modi-
ﬁcation. BAP1 loss-of-function mutations have been
described as sensitizing cancer cells to ionizing radiation
and poly(adenosine diphosphate–ribose) polymerase
(PARP) inhibition,11,12 indicating a role of functional
BAP1 in promoting DSB repair.
While investigating BAP1 transcripts in MPM cell
lines, we identiﬁed by serendipity a novel splice variant
of BAP1 (BAP1D) missing part of the catalytic domain.
The expression of splice variants is not unusual in
cancer because it often offers a survival advantage.13 We
have previously described14 alternative splicing events
occurring in neuroﬁbromin 2 (NF2), another frequently
mutated tumor suppressor with a driver role in this
disease.15–19 NF2 transcripts undergo alternative
splicing, generating multiple isoforms.20 Isoform I, which
is missing exon 16, and isoform II, which contains all 17
exons, are the two predominant species. However, only
isoform I functions as a tumor suppressor and its activity
is phosphorylation dependent.21,22 We have observed
that 4% of tumor samples displayed isoform II only.
Additionally, the splicing variant delE2/3, which is
functionally associated with tumor development in
transgenic mice if overexpressed in the absence of wild-
type (WT) NF2,23 was expressed in 35% of the MPM
samples and in one sample of the inﬂammation and
normal pleura.
In this study, our aim was to functionally characterize
BAP1D and investigate whether its expression could be
exploited for therapy.
Material and Methods
Cell Culture
The mesothelioma cell lines ZL55, ZL34, SPC111,
MSTO-211H, ACC-Meso-1, and Mero8 and SDM104
normal mesothelial cells were cultured as previously
described.24 HEK293 cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% fetal calf serum (FCS) and 1% penicillin/
streptomycin. Transfected ZL55 cells were selected with
puromycin. The breast cancer cell line MCF-7 was kindly
provided by Dr. Stucki (Clinic for Gynecology, University
Hospital Zürich, Zürich, Switzerland) and maintained in
Roswell Park Memorial Institute medium, 10% FCS, and
1% penicillin/streptomycin. All cells were kept at 37C
in a humidiﬁed 5% CO2 incubator.
Tumor Specimens
Tumor specimens were obtained for diagnostic pur-
poses before chemotherapy or at the time of resection.25
Normal pleural tissue was received from patients un-
dergoing a mesothelioma-unrelated thoracic operation.25
The study was approved by the University Hospital
Zürich ethics committee and written informed consent
was obtained from all patients. Twenty RNA samples
were selected on the basis of BAP1 determined to be WT
by using next-generation sequencing (Oehl and Wild,
Institute of Surgical Pathology, Zürich University Hospi-
tal, manuscript in preparation) and being representative
of the three MPM histologic forms: 16 of 20 epithelial
(80%), three of 20 biphasic (15%), an one of 20 sarco-
matoid (w1%).
Reagents
Dulbecco’s modiﬁed Eagle’s medium–F12 medium
and penicillin/streptomycin 100x stock solution were
purchased from Sigma-Aldrich Chemie GmbH (Buchs,
Switzerland). Trypsin–ethylenediaminetetraacetic acid
0.25% 1 solution and Opti-MEM medium were
purchased from Gibco (Life Technologies Europe, Zug,
Switzerland). FCS (CVFSVF00-01) and puromycin
were purchased from Eurobio (Les Ulis, France) and
from AppliChem (Darmstadt, Germany), respectively.
Olaparib (AZD2281, Ku-0059436) was purchased
from Selleckchem (Luzern, Switzerland), and GDC-0980
was obtained from Genentech (Roche, Basel,
Switzerland). DMRIE-C was purchased from Invitrogen
(Carlsbad, CA).
RNA Extraction, Complementary DNA Synthesis,
and Quantitative PCR
Total RNA (0.5 mg) extracted from cells, nontumoral
tissue, tumors, or a pool of 12 spheroids with the
RNeasy Isolation Kit (Qiagen, Hilden, Germany) was
reverse-transcribed with the Quantitect Reverse
Transcription Kit (Qiagen). Quantitative polymerase
chain reaction (PCR) was performed as previously
described.14 The primers are listed in Supplementary
Table 1.
Protein Extraction and Western Blotting
Total protein extracts were obtained by lysing
the cells with assay buffer (Sigma Aldrich) containing
50 mM Tris-HCl, pH 8.0, with 150 mM sodium
chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium
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deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)
supplemented with additional SDS to a ﬁnal concentra-
tion of 1% and protease inhibitors, passing it through a
syringe and keeping it in ice for 15 minutes. Core his-
tones were obtained by acidic extraction as previously
described.26 Cytosolic and nuclear protein extracts were
isolated by using the NE-PER Nuclear and Cytoplasmic
Extraction Kit (Pierce Biotechnology, Waltham, MA) ac-
cording to the manufacturer’s instructions and nuclear
versus cytosolic purity controls were assessed by
probing with anti-PARP (Cell Signaling Technology,
Danvers, MA) and anti-vinculin antibodies, respectively.
Protein concentration was determined by using the
Bradford protein assay and proteins were prepared by
adding 6 reducing Lämmli buffer and boiling for
5minutes. Five or 10mg of total proteins or 0.5 mg of
puriﬁed histones were separated on denaturing 4% to
20% gradient SDS–polyacrylamide gel electrophoresis
gels, 3% to 8% gradient precast acrylamide, or 15%
SDS–polyacrylamide gel electrophoresis gels depending
on the target and transferred onto 0.45-mm poly-
vinylidene ﬂuoride transfer membranes (Perkin Elmer,
Schwerzenbach, Switzerland). The membranes
were probed with the following primary antibodies:
mouse anti-BAP1 (C4), rabbit anti-histone H2A, mouse
anti-histone H3, mouse anti-gH2AX, mouse anti-b-actin,
rabbit anti-poly(adenosine diphosphate–ribose), rabbit
anti-phospho-S6 (Ser235/236), mouse anti-S6, and
mouse anti-BRCA1. As a positive control for phospho-S6
(Ser235/236), cell extracts from Mero-83 cells24 were
used. Membranes were then incubated with the
secondary antibody goat anti-mouse immunoglobulin
G–horseradish peroxidase from Ancell (Bayport, MN) and
goat anti-rabbit immunoglobulin G–horseradish peroxi-
dase from Cell Signaling Technology. The signals were
detected by enhanced chemiluminescence (ECL Western
Blotting Reagents, GE Healthcare, Glattbrugg,
Switzerland) and detected on photosensitive ﬁlm (Super
RX Fuji X-Ray Film, Fujiﬁlm, Düsseldorf, Germany).
Proteins were quantitated with densitometry by using
Image J software, version 1.42q (National Institutes of
Health, Bethesda, MD). The percentage of nuclear BAP1
was calculated in single complementary DNA (cDNA)-
transfected cells as follows. Nuclear versus cytosolic
BAP1, either BAP1D or BAP1FL, was normalized to PARP
versus vinculin, respectively, and their sum was consid-
ered as total BAP1. Nuclear BAP1 was calculated as the
fraction of total BAP1. In addition, because in
coexpression experiments we observed the accumulation
of high-molecular forms of BAP1, we quantiﬁed all the
bands with a molecular weight higher than that of BAP1D
and normalized them to PARP versus vinculin, respec-
tively, to estimate their accumulation in the nuclear
versus the cytosolic fraction.
BAP1 Cloning, Sequencing, and Transfection
Human BAP1 and BAP1D cDNA ampliﬁed from MPM
cell lines were subcloned into the NotI site of the
pCI-puro vector, which contains a puromycin resistance
gene,27 and inserts were validated by sequencing and
deposited in Addgene (68365 and 68366, respectively).
All primers are indicated in Supplementary Table 1.
HEK293 cells were transfected with control vector,
pCI-Puro_BAP1FL, or pCI-Puro_BAP1D by using DMRIE-
C or Lipofectamine 2000 reagent (Invitrogen) according
to the manufacturer’s instruction. To test the interaction
between the two BAP1 isoforms, ZL55 cells stably
expressing control vector or pCI-Puro_BAP1FL were
transiently transfected with increasing amounts of
pCI-Puro_BAP1D.
Clonogenic Assay
Colony formation assays were performed as follows:
200 cells were plated in six-well plates and subjected to
treatment with different concentrations of a speciﬁc
drug after 1 and 5 days. After an additional 5 days, cells
were stained with crystal violet and colonies were
counted by eye.
Immunoﬂuorescence
ZL55 cells transfected with BAP1FL or BAP1D were
ﬁxed for 10minutes with 4% paraformaldehyde,
permeabilized with 0.1% TX-100 for 10minutes, and
blocked with phosphate-buffered saline containing 1%
bovine serum albumin and 1% normal goat serum
before incubation overnight at 4C with Bap1 antibody.
Alexa Fluor 488 goat anti-mouse (Life Technologies)
antibody was then added for 1 hour at room tempera-
ture. Coverslips were mounted using Prolong Gold
antifade reagent containing 4,6-diamino-2-phenylindole
(Life Technologies). Images were acquired using a
Leica DM6000 confocal microscope (Leica Biosystems,
Nussloch, Germany).
Spheroid Formation and Viability Assay
Spheroid formation assays were performed as
previously described.24 At day 4 after seeding, the
spheroids were treated with different drugs for 6 days
and viability was analyzed using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Dübendorf,
Switzerland) to determine the adenosine triphosphate
(ATP) content. Luminescence was acquired by using a
GloMax 96 Microplate Luminometer (Promega). Each
experiment was performed in triplicate.
Phylogenetic Analysis
Multiple alignments of the protein sequences have been
performed throughMAFFT FFT-NS-i (v7.215) (http://mafft.
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cbrc.jp/alignment/server/). Aphylogenetic treewas created
with Molecular Evolutionary Genetics Analysis software
and the following sequences were obtained from the
National Center for Biotechnology Information: Homo
sapiens (reference sequence [ref seq] XM_017007303.1),
Pongo abelii (ref seq XM_009238935.1), Mandrillus
leucophaeus (ref seq XM_011986223.1), Colobus
angolensis palliates (ref seq XM_011958849.1), Chlorocebus
sabaeus (ref seq XM_007984488.1), Rhinopithecus
roxellana (ref seq XM_010365018.1), Tupaia chinensis
(ref seq XM_006169325.2), Pteropus vampyrus (ref
seq XM_011372563.1), Pteropus alecto (ref seq
XM_015593797.1), Bos taurus (ref seq NM_001102549.1),
Ovis aries (ref seq XM_012099955.2), and Loxodonta
africana (ref seq XM_010589758.1).
Statistical Analysis
Statistical analysis was performed with GraphPad
Prism software, version 5.04 (GraphPad Software, La
Jolla, CA). Data are presented as the average plus or
minus SD. To determine signiﬁcant additive effects
between combination treatments and inhibition of cell
death with the inhibitors, an analysis of variance test
was performed. Differences with a p value less than 0.05
were considered signiﬁcant.
Results
Identiﬁcation and Characterization of a Novel
BAP1 Splice Variant
While investigating BAP1 transcripts in MPM cell lines,
we identiﬁed a shorter variant (BAP1D) missing 54 base
pairs within exon 9 compared with the full-length BAP1
(BAP1FL) (Fig. 1A). On the basis of data on the crystal
structure of the UCH domain (https://www.ncbi.nlm.nih.
gov/Structure/cdd/cddsrv.cgi?ascbin¼8&maxaln¼10
&seltype¼2&uid¼187738&querygi¼508123781&aln¼4,
10,0,32,42,33,63,106,96,51,157,150,69), BAP1D is
missing 12 amino acids of the catalytic region and part of
the BARD1 binding domain and has been already listed as
BAP1 transcript in the Ensembl database. It may result
from a second acceptor site (http://www.umd.be/HSF3/
index.html), which is almost as strong as the one for
Figure 1. Identiﬁcation of a novel BRCA associated protein1 (BAP1) splice variant (BAP1D). (A) Schematic representation of a
coding sequence and protein domains of full-length BAP1 (BAP1FL) and BAP1D. (B) Phylogenetic tree of the protein sequences
of BAP1D. The phylogenetic analysis indicated that the ﬁrst appearance of BAP1D dates back to approximately 150 million of
years ago. UCH, ubiquitin carboxyl hydrolase; BARD1, BRCA1 associated RING domain 1; HCFC1, host cell factor C1; BRCA1,
BRCA1, DNA repair associated; UTR, untranslated region; NLS, nuclear localization signal; bp, base pair.
4 Parrotta et al Journal of Thoracic Oncology Vol. - No. -
BAP1FL. BAP1D is present in several species, and multi-
species sequence alignment and phylogeny analysis
revealed that BAP1D appeared ﬁrst in placentals, dating
back to approximately 150 million years ago (Fig. 1B and
Supplementary Data 1). A fragment covering the region of
alternative splicing was ampliﬁed by PCR, which revealed
the expression of both BAP1FL and BAP1D in MPM
(Fig. 2A). Using a set of primers that allows detection of
BAP1D speciﬁcally,wedetected theBAP1D isoform inboth
MPM cell lines and tumors (Fig. 2B). Interestingly, BAP1D
was less abundant in tumors expressing WT BAP1 than in
nontumor samples (Fig. 2C).
HEK293 cells transfected with BAP1FL (Fig. 3A)
showed a reduction of monoubiquitinated H2A, whereas
no change was observed in the cells expressing BAP1D
(Fig. 3B and Supplementary Fig. 1), conﬁrming that the
deubiquitinase activity of this splice variant is impaired,
which is consistent with our prediction based on the
sequence. We transfected BAP1-deﬁcient ZL55 meso-
thelioma cells with BAP1FL or BAP1D; then, using
immunoﬂuorescence analysis, we determined that
BAP1D localizes to the nucleus, however, not to the same
extent as BAP1FL (Fig. 3C). This observation was
conﬁrmed in experiments in which ZL55 cells stably
expressing control vector or pCI-Puro_BAP1FL were
transiently transfected with increasing amounts of
pCI-Puro_BAP1D, after which cytosolic versus nuclear
fractions were isolated. Addition of BAP1D resulted in
increased levels of high-molecular-weight bands with
BAP1 immunoreactivity in total lysates (Fig. 3D). Quan-
tiﬁcation of cellular fractionation experiments in single
cDNA-expressing cells revealed a 53% plus or minus 4%
decrease in nuclear accumulation of BAP1D compared
with BAP1FL, as estimated by comparing the percentage
of normalized BAP1 immunoreactivity present in the
nucleus (Fig. 3E and Supplementary Fig. 1). In cells
coexpressing BAP1FL and BAP1D, the quantiﬁcation of
BAP1FL as the sum of molecular forms higher than
BAP1D (see Fig. 3E) indicated a shift in BAP1 distribu-
tion from nucleus to cytosol (Fig. 3F).
Figure 2. Characterization of BRCA associated protein1 (BAP1) splice variant (BAP1D). Detection of full-length BAP1
(BAP1FL) and BAP1D in a representative malignant pleural mesothelioma (MPM) cell line (A) and different level of BAP1D
expression in MPM cell lines and tumor samples (B). (C) Quantitative polymerase chain reaction of BAP1D in wild-type BAP1–
expressing tumors and nontumor samples. Ctrl, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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Role of BAP1D in MPM Sensitization to PARP
Inhibitor
To assess the relevance of BAP1D expression in MPM,
we used transfected ZL55 cells to assess cell survival
after treatment with olaparib, a drug known to be more
potent in BAP1-deﬁcient cells.11,12 Basal levels of protein
poly adenosine diphosphate–ribosylation (PARylation),
which is indicative of PARP activity were detected, which
was consistent with what had been already observed in
glioma spheroids,28 and they decreased after olaparib
treatment (Fig. 4A). We could observe a twofold to
threefold increase in cytotoxicity of the drug in BAP1D-
transfected cells compared with in BAP1FL-transfected
cells in both clonogenic (Fig. 4B) and spheroid viability
assays (Fig. 4C).
Both Levels of BAP1D and GDC0980-Mediated
BRCA1 Depletion Sensitize to Olaparib
Inhibition of PARP is an established therapeutic
strategy for breast and ovarian cancer in BRCA1-deﬁcient
tumors.29 As expected,30 we observed an increased
phosphorylation of histone H2AX, a known marker of
DNA DSBs, upon treatment with olaparib in MPM
spheroids (Supplementary Fig. 2), suggesting engage-
ment of BRCA1 in DNA repair.31,32 Because BAP1 can
interact with BRCA1 and because BAP1FL reconstitution
in BAP1-null cell lines leads to resistance to PARP
inhibition (unlike in BAP1D-reconstituted cells), we
analyzed the expression of BAP1D compared with
expression of BAP1FL in MPM cell lines. Sequencing
revealed the presence of WT BAP1 in all tested cell lines.
We grouped them in two groups: low BAP1D, with a
BAP1D/BAP1 expression ratio value of 20% or less
(Mero82, ACC-Meso1, SDM103T2, H2052) and high
BAP1D (BAP1Dhigh), with a BAP1D/BAP1 expression
ratio value greater than 20% (MSTO-211H, SPC111, ZL34,
and Mero41) (Fig. 5A). The threshold value of 20%
represents the median of BAP1D/BAP1 in the MPM cell
lines. We then tested whether BRCA1 depletion mediated
by phosphoinositide 3–kinase (PI3K) pathway
inhibition33 would sensitize MPM cells to PARP inhibition
in MPM cell lines able to form spheroids. Spheroids were
treated individually with olaparib or in combination with
Figure 3. Defective deubiquitinating activity and nuclear localization of BRCA associated protein1 (BAP1) splice variant
(BAP1D). (A) HEK293 cells were transiently transfected with empty vector (EV) or with full-length BAP1 (BAP1FL) and BAP1D
cDNA. (B) Core histones were isolated by acidic extraction26 and Western blot was performed to detect monoubiquitination
levels of histone H2A (K119Ub-H2A). Results are representative of three independent experiments. (C) ZL55 cells transfected
with BAP1FL and BAP1D cDNA were analyzed for BAP1 immunoreactivity by immunoﬂuorescence. ZL55 cells expressing
EV or BAP1FL were transfected with increasing amounts of BAP1D cDNA (D) and BAP1 subcellular distribution was analyzed
(E). Parentheses indicate bands considered as BAP1FL and BAP1D in the quantiﬁcation of nuclear versus cytosolic fraction.
(F) Quantiﬁcation of cytosolic and nuclear BAP1FL (including high-molecular-weight forms) in the absence or presence
of coexpression of BAP1D (n ¼ 3). DAPI, 4,6-diamino-2-phenylindole; C, cytosolic extract; N, nuclear extract; PARP,
poly(adenosine diphosphate–ribose) polymerase.
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GDC0980, a dual PI3K–mammalian target of rapamycin
(mTOR) inhibitor. As expected, phosphorylated protein
S6 (downstream effector of PI3K-mTOR pathway) levels
decreased after GDC0980 treatment in spheroids, as we
had previously observed in two-dementional models24
(Fig. 5B). BRCA1 expression was reduced as expected
after GDC0980 treatment in the two cell lines repre-
senting the low BAP1D and BAP1Dhigh groups selected on
the basis of similar total BAP1 levels. Moreover, BRCA1
downregulation was intensiﬁed in the BAP1Dhigh cell line
SPC111 when treated with the combined treatment
(Fig. 5C). BAP1D/BAP1 high ratio sensitized MPM cell
lines to olaparib (Fig. 5D and E). As previously shown,
GDC0980 decreased ATP content24 and the BAP1Dhigh
group showed a complete ATP drop with the combined
treatment (see Fig. 5E). Spheroids derived from the
normal mesothelium cell line SDM104 were resistant to
olaparib and, as previously described, were growth
inhibited by GDC0980.24 ATP content decreased further
by the combined treatment, albeit to a lesser extent
compared with mesothelioma cells (see Fig. 5E).
Discussion
In this study we showed that expression of the
BAP1D isoform over a threshold level, deﬁned as 20% of
total BAP1, sensitizes MPM cells expressing WT BAP1 to
olaparib-induced cytotoxicity. Combining this treatment
with PI3K-mTOR inhibitors, which decrease BRCA1
levels, results in stronger effects.
Figure 4. BRCA associated protein1 (BAP1) splice variant (BAP1D) sensitizes malignant pleural mesothelioma cells to olaparib
in two- and three-dimensional in vitro cell survival assays. (A) Olaparib decreased poly adenosine diphosphate–ribosylation in
spheroids. H2O2-induced activation of PARP1 resulting in poly adenosine diphosphate–ribosylation of proteins served as a
positive control for poly(adenosine diphosphate–ribose) (PAR) immunoblot. Cells expressing BAP1D were as sensitive as BAP1-
deﬁcient cells to olaparib in two- (B) and three-dimensional (C) models. Results derived from three independent experiments
performed in triplicate. *p < 0.05; ***p <0.001; ****p < 0.0001. EV, empty vector; BAP1FL, full-length BAP1; ATP, adenosine
triphosphate.
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Figure 5. BRCA associated protein1 (BAP1) splice variant (BAP1D) expression level and inhibition of phosphoinositide
3–kinase–mammalian target of rapamycin sensitize malignant pleural mesothelioma (MPM) cells to olaparib. (A) Relative
expression of BAP1D and full-length BAP1 (BAP1FL) in MPM. (B) GDC0980 decreased phosphorylation of protein S6 (p-S6) in
MPM spheroids. (C) BRCA1 levels in three-dimensional spheroids obtained from Mero8p-s62 and SPC111 cells untreated
(DMSO) and treated with 20mM olaparib or 0.5 mM GDC0980 individually or in combination. MCF7 cells lysate was included as
positive control for BRCA1 expression. (D) Representative light micrographs of Mero-82 and SPC111 spheroids treated with 20
mM olaparib and 0.5 mM GDC0980. (E) Effect of combined olaparib and GDC-0980 in MPM cell lines grouped on the basis of high
(BAP1Dhigh) and low (BAP1Dlow) expression of BAP1D or in normal mesothelial cells SDM104. Results derived from three
independent experiments performed in triplicate. ***p < 0.001. BAP1FL, full-length BAP1.
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Deﬁciency in processes involved in DNA damage
response can be exploited as a therapeutic strategy. For
example, when DNA single-strand breaks occur, cells
undergo PARP-mediated DNA repair. If this mechanism
is inhibited (e.g., by olaparib), single-strand breaks
persist and turn into DSBs. When these accumulate, they
become lethal for cancer cells when speciﬁc DNA repair
processes (such as homologous recombination) are
impaired, as in the case of BRCA-deﬁcient breast and
ovarian cancer.29 Interestingly, the expression of BRCA1
is essential in mediating apoptosis induced by vinor-
elbine (an antimitotic drug used in second-line therapy)
in MPM cells,34 and low BRCA-1 expression and vinor-
elbine resistance were observed in about 40% of pa-
tients with MPM. However, it remains unclear whether
this is due to BAP1 loss of function (especially because
recent studies have suggested a role of BAP1 in BRCA1
stabilization in mesothelioma35) or to some other
mechanism in which BAP1D might be involved. Homol-
ogous recombination deﬁciency can also be induced by
impairing BRCA1 expression through PI3K inhibition,
resulting in cell sensitization to PARP inhibition.33
In our study we characterized a novel isoform of
BAP1 that exhibits diminished deubiquitinating activity
on histone H2A and is very likely unable to exert its
function in DNA repair. The association between alter-
native splicing and cancer is rapidly emerging, because
isoforms of a protein can have opposite functions.36 The
appearance of this isoform in placentals may reﬂect
functional requirements unique to placental mammals,
as is the case for other chromatin modiﬁers.37 Interest-
ingly, the alternative acceptor site for BAP1D scores
almost as high as the one for BAP1FL, and therefore,
exonic splicing enhancers38 may possibly play a role in
the differential expression. BAP1D was still able to enter
the nucleus; therefore, a possible mechanim of action is
interference with BAP1FL dimerization with ASLX139
and consequent inactivation. Another intriguing possi-
bilty is inferred by the appearance of higher-molecular-
weight forms of BAP1 after coexpression of BAP1FL
and BAP1D. The higher molecular weight may represent
ubiquitin conjugating enzyme E2 O-dependent ubiquitin-
conjugated forms of BAP1, which accumulate especially
when BAP1 cannot efﬁciently deubiquinate itself.40
Although further investigations that are beyond the
scope of this study are necessary to elucidate the
underlying mechanism of BAP1D interference with
BAP1FL, we have demonstrated that expression of
BAP1D over a certain threshold level, even in the pres-
ence of functional BAP1, could be exploited in combi-
nation with PI3K-mTOR inhibitors in a therapeutic
approach using PARP inhibitors.
Potential synthetic lethality between PARP and PI3K/
mTOR inhibition has been recently documented in
several models,33,41–43 and besides decreasing BRCA1
expression, other mechanisms involve nucleotide
depletion.41 Olaparib is a U.S. Food and Drug Adminis-
tration–approved targeted therapy in cancer,29 and
GDC0980 has proved to have some efﬁcacy in a clinical
study, especially in patients with mesothelioma44;
therefore, this strategy is potentially easy to implement
in a clinical trial. Because BAP1 is WT in 77% of MPMs,45
15% of patients with MPM could potentially beneﬁt from
this therapeutic strategy.
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